Astellas collaborates with Mass General Brigham for translational medicine

  • Astellas Pharma (OTCPK:ALPMY) entered into a strategic collaboration with Mass General Brigham (President and CEO: Anne Klibanski, MD) that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.
  • It would be a five-year collaboration to advance translational medicine and accelerate early development of novel therapies with focus on oncology, rare disease, and cell and gene therapies.
  • This collaboration will leverage Mass General Brigham’s clinical and research expertise, and capabilities including clinical data and human-derived cell models.

Roy Walsh

Related post